Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Drug Profile

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Alternative Names: BGB 324; R-428

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Benzocycloheptenes; Cycloheptanes; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; Malignant melanoma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Pancreatic cancer
  • Preclinical Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • No development reported Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 22 Oct 2019 Bemcentinib receives fast track designation from the US FDA for Acute myeloid leukaemia (Second-line therapy or greater, In the elderly)
  • 14 Jun 2019 Efficacy data and adverse events data from a phase Ib/II BGBC003 trial in Acute myeloid leukaemia presented at the 24th Congress of the European Haematology Association (EHA-2019)
  • 14 Jun 2019 Updated efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 24th Annual Congress of the European Hematology Association (EHA-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top